As previously communicated, this transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share (EPS) by approximately $0.20.

Under the terms of the definitive agreement with Abbott, upon completion of the transaction, Exact Sciences' stockholders will be entitled to receive $105.00 in cash, without interest and subject to any applicable withholding taxes, for each share of Exact Sciences common stock they owned as of immediately before the completion of the transaction.